z-logo
Premium
High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group
Author(s) -
Ho Phoenix A.,
Alonzo Todd A.,
Gerbing Robert B.,
Pollard Jessica A.,
Hirsch Betsy,
Raimondi Susana C.,
Cooper Todd,
Gamis Alan S.,
Meshinchi Soheil
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12444
Subject(s) - medicine , myeloid leukaemia , multivariate analysis , myeloid , oncology , polymerase chain reaction , survival analysis , gastroenterology , immunology , biology , genetics , gene
Summary Ectopic viral integration site‐1 ( EVI 1) is highly expressed in certain cytogenetic subsets of adult acute myeloid leukaemia ( AML ), and has been associated with inferior survival. We sought to examine the clinical and biological associations of EVI 1 high , defined as expression in excess of normal controls, in paediatric AML . EVI 1 m RNA expression was measured via quantitative real‐time polymerase chain reaction in diagnostic specimens obtained from 206 patients. Expression levels were correlated with clinical features and outcome. EVI 1 high was present in 58/206 (28%) patients. MLL rearrangements occurred in 40% of EVI 1 high patients as opposed to 12% of the EVI 1 low/absent patients ( P  < 0·001). No abnormalities of 3q26 were found in EVI 1 high patients by conventional cytogenetic analysis, nor were cryptic 3q26 abnormalities detected in a subset of patients screened by next‐generation sequencing. French‐American‐British class M7 was enriched in the EVI 1 high group, accounting for 24% of these patients. EVI 1 high patients had significantly lower 5‐year overall survival from study entry (51% vs. 68%, P  = 0·015). However, in multivariate analysis including other established prognostic markers, EVI 1 expression did not retain independent prognostic significance. EVI 1 expression is currently being studied in a larger cohort of patients enrolled on subsequent Children's Oncology Group trials, to determine if EVI 1 high has prognostic value in MLL ‐ rearranged or intermediate‐risk subsets.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom